ABSTRACT: Control of elemental impurities in pharmaceutical materials is currently undergoing a transition from control based on concentrations in components of drug products to control based on permitted daily exposures in drug products.Within the pharmaceutical community, there is uncertainty regarding the impact of these changes on manufactures of drug products. This uncertainty is fueled in part by a lack of publically available information on elemental impurity levels in common pharmaceutical excipients. This paper summarizes a recent survey of elemental impurity levels in common pharmaceutical excipients as well as some drug substances. A widely applicable analytical procedure was developed and was shown to be suitable for analysis of elements that are subject to United States Pharmacopoeia Chapter <232> and International Conference on Harmonization’s Q3D Guideline on Elemental Impurities. The procedure utilizes microwave-assisted digestion of pharmaceutical materials and inductively coupled plasma mass spectrometry for quantitative analysis of these elements. The procedure was applied to 190 samples from 31 different excipients and 15 samples from eight drug substances provided through the International Pharmaceutical Excipient Council of the Americas. The results of the survey indicate that, for the materials included in the study, relatively low levels of elemental impurities are present.
1U.S. Food and Drug Administration, Division of Pharmaceutical Analysis, St. Louis, Missouri 63110
2Colorcon Inc., Harleysville, Pennsylvania 19438
3Dow Corning Healthcare Business, Midland, Michigan 48686-0994
4Dow Corning Analytical Sciences, Midland, Michigan 48686-0994
5IPEC-Americas, Arlington, Virginia 22201
Received 14 May 2015; revised 26 August 2015; accepted 28 August 2015
Published online 23 September 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.24650